在与年龄相关的神经疾病中准神经Alpha7尼古丁性乙胆受体升调
Sharon Mariam Abraham1, Sneha Suresh2, Pragya Komal3
1Department of Biological Sciences, Birla Institute of Technology and Science (BITS-Pilani), Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Medchal District, Hyderabad, 500078, Telangana, India.
Cellular and molecular neurobiology
|July 16, 2025
概括
维生素D3 (VD) 补充剂可以通过增强α7尼古丁性乙胆受体 (α7nAChRs) 来恢复大脑功能. 本综述探讨了α7nAChRs和VD的独特特性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 阿尔法7尼古丁性乙胆受体 (α7nAChRs) 对于认知增强,神经保护和抗炎作用至关重要.
- 它们的高透性和通过翻译后修饰 (PTM) 的调节强调了它们在神经元通信中的独特作用.
- 功能障碍和α7nAChRs的丧失与神经退行,认知障碍和各种神经系统疾病中的记忆缺陷有关.
研究的目的:
- 审查α7nAChRs对大脑功能至关重要的独特特性.
- 检查维生素D3 (VD) 在解决α7nAChR功能障碍方面的治疗潜力.
- 突出VD在神经精神和神经疾病中恢复胆固醇神经传递和α7nAChR表达中的作用.
主要方法:
- 对α7nAChRs和维生素D3现有研究的文献综述3.
- 分析研究的分析,调查VD对胆固醇通路的影响.
- 关于VD对α7nAChR表达和功能的影响的综合证据.
主要成果:
- 有证据表明,静脉疾病补充剂在许多神经系统疾病中提供认知益处.
- 静脉疾病可能在恢复胆固醇神经传递方面发挥作用.
- 血管疾病补充剂在正常化受影响大脑区域α7nAChR表达方面显示出有前途.
结论:
- α7nAChRs的独特特性对于保持大脑健康至关重要.
- 维生素D3成为神经系统疾病的潜在治疗剂,其特点是胆固醇缺乏.
- 对静脉疾病机制的进一步研究可能会导致对认知和神经退行性疾病的新型治疗策略.
相关概念视频
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
01:26Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
843
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
843
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
212
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
212
01:37Neural Regulation
40.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.2K
01:15Cholinergic Receptors: Nicotinic
3.8K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
3.8K